AlphaCentric Advisors LLC Invests $350,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AlphaCentric Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 491 shares of the biopharmaceutical company’s stock, valued at approximately $350,000.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. State Street Corp raised its position in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. International Assets Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Swiss National Bank lifted its position in Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after buying an additional 2,000 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after buying an additional 1,108 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $673.60 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a market cap of $74.02 billion, a P/E ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The stock’s fifty day moving average price is $706.92 and its 200-day moving average price is $896.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the firm posted $11.86 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 36.67 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.52%.

Analysts Set New Price Targets

Several research analysts recently issued reports on REGN shares. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price target for the company. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. TD Cowen cut their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Finally, Barclays lowered their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.